Reversal of target-specific oral anticoagulants

@article{Kaatz2013ReversalOT,
  title={Reversal of target-specific oral anticoagulants},
  author={Scott Kaatz and Mark Crowther},
  journal={Journal of Thrombosis and Thrombolysis},
  year={2013},
  volume={36},
  pages={195-202}
}
The target-specific oral anticoagulants represent the first new oral anti-thrombotic therapy in over 50 years and have the potential to make therapy easier and hence more accessible to many patients. Like any new therapy, the potential benefits must be weighed against the potential challenges and one of the most concerning aspects of the new target-specific oral anticoagulants is the lack of a proven method to reverse their effect. Unlike the vitamin K antagonist, i.e. warfarin, there is no… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
1 Extracted Citations
30 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 30 references

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model

  • A Godier, A Miclot, +5 authors CM Samama
  • 2012

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94–102

  • A Godier, A Miclot, +6 authors CM Samama
  • 2012
2 Excerpts

Similar Papers

Loading similar papers…